Literature DB >> 9031114

Hodgkin's disease variant of Richter's syndrome: experience at a single institution.

L Fayad1, L E Robertson, S O'Brien, J T Manning, S Wright, F Hagemeister, F Cabanillas, M J Keating.   

Abstract

Patients developing Hodgkin's disease (HD) after a diagnosis of chronic lymphocytic leukemia (CLL), are frequently included in a series of patients with Richter's syndrome (RS). We sought to determine the natural history of the association of CLL and HD. Over a 21 year period, 1374 patients with CLL have been registered in our computer data base. Seven cases of CLL and HD have been documented and confirmed. The median age of these patients was 71 years (range 44-77) and clinical features included male gender (86%), B symptomatology (86%), rapidly progressive lymphadenopathy (71%), prior CLL therapy (71%), advanced Ann Arbor stage (86%), marrow involvement with HD (43%), and autoimmune hemolytic anemia (29%). HD was documented by excisional lymph node biopsy in six cases and splenectomy in one. Mixed cellularity HD was shown in six and nodular sclerosis in one. Five of the biopsies revealed intervening areas consistent with small lymphocytic lymphoma. The Sternberg-Reed (SR) cells were CD15+ in 6/7 cases, and Ki-1+ in the 6 patients tested. CD45 and CD20 staining of the SR cells was nonreactive. The median time to development of HD was 45 months (range 0 to 96). The overall responses to different chemotherapy regimens was approximately 25% with only one CR. Six patients have died at 3, 9, 10, 13, 15 and 36 months and one patient is alive with progressive disease at 11 months. Our data suggests that CLL patients have a heightened risk for HD, features of advanced HD on presentation, and a poor response rate with short survival.

Entities:  

Mesh:

Year:  1996        PMID: 9031114     DOI: 10.3109/10428199609054836

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

Review 1.  Recent advances in the diagnosis and therapy of Richter's syndrome.

Authors:  Ronan Swords; John Bruzzi; Francis Giles
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

2.  Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor?

Authors:  Riccardo Dolcetti; Antonino Carbone
Journal:  Infect Agent Cancer       Date:  2010-11-22       Impact factor: 2.965

3.  Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma.

Authors:  Sameer A Parikh; Thomas M Habermann; Kari G Chaffee; Timothy G Call; Wei Ding; Jose F Leis; William R Macon; Susan M Schwager; Kay M Ristow; Luis F Porrata; Neil E Kay; Susan L Slager; Tait D Shanafelt
Journal:  Am J Hematol       Date:  2015-01-30       Impact factor: 10.047

4.  Hodgkin lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors:  John R Krause; Lee C Drinkard; Latoya C Keglovits
Journal:  Proc (Bayl Univ Med Cent)       Date:  2013-01

5.  Hodgkin's disease variant of Richter's transformation: a case report.

Authors:  Abdurrahman Isikdogan; Orhan Ayyildiz; Hüseyin Büyükbayram; Ekrem Müftüoğlu
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

6.  The spectrum of coincident entities with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) diagnosed by cytology.

Authors:  Hannah A Kastenbaum; Walid E Khalbuss; Raymond E Felgar; Ronald Stoller; Sara E Monaco
Journal:  Cytojournal       Date:  2010-10-11       Impact factor: 2.091

7.  Hodgkin lymphoma transformation of chronic lymphocytic leukemia: cases report and discussion.

Authors:  Maciej Kaźmierczak; Renata Kroll-Balcerzak; Andrzej Balcerzak; Elżbieta Czechowska; Lidia Gil; Krzysztof Sawiński; Andrzej Szczepaniak; Mieczysław Komarnicki
Journal:  Med Oncol       Date:  2013-12-15       Impact factor: 3.064

Review 8.  Novel Approaches for the Treatment of Patients with Richter's Syndrome.

Authors:  Andrea Iannello; Silvia Deaglio; Tiziana Vaisitti
Journal:  Curr Treat Options Oncol       Date:  2022-03-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.